OTC:ACBM
ACRO BIOMEDICAL CO., LTD.
ACRO Biomedical Co., Ltd. (ACBM) is an OTC-listed medical device developer facing severe liquidity constraints and zero revenue in recent periods.
Key Metrics
Investment Thesis
Bull Case
An investor might consider ACBM if they believe the company can secure emergency capital to extend its runway and successfully commercialize its dormant product pipeline. The stock represents a deep value play for contrarian investors willing to accept extreme dilution risk in exchange for potential 10x returns upon a successful IPO or strategic acquisition by a major medical device firm.
Bear Case
The stock is fundamentally broken with zero revenue, massive liabilities dwarfing assets, and a retained earnings deficit that jeopardizes the company's existence. Any investment carries an extreme probability of total capital loss as the firm struggles to generate positive cash flow from operations or attract further funding in a challenging OTC market environment.
About ACRO BIOMEDICAL CO., LTD.
ACRO Biomedical Co., Ltd. specializes in the development and commercialization of novel medical devices and diagnostic solutions, primarily targeting the global healthcare market. The company leverages proprietary technology to address unmet clinical needs, though recent financial filings indicate a period of significant operational contraction with zero reported revenue for the latest fiscal year. With a substantial cash burn and negative retained earnings, the firm is currently navigating critical liquidity challenges while attempting to validate its core product pipeline.
Analysis
Management Discussion
The company's financial performance has deteriorated sharply, evidenced by a net loss of $101.1M in the latest period and zero revenue reported. Operating expenses consumed nearly all available resources while cash from operations turned significantly negative, reducing total cash reserves from $4.7M to just over $4K. Despite a large one-time financing inflow of nearly $200M previously recorded, the current operating reality suggests an unsustainable burn rate that has eroded equity by over $386M.
Industry Overview
The global medical device industry is valued in the hundreds of billions, driven by aging populations and technological advancements in diagnostics and surgical tools. While the sector typically rewards innovation with high margins, early-stage companies face immense hurdles in regulatory approval, commercialization costs, and maintaining liquidity until profitability is achieved.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $658.5K | $0 | $0 | $0 |
| Cost of Revenue | $518.0K | $0 | $0 | $0 |
| Gross Profit | $140.5K | $0 | $0 | $0 |
| Operating Expenses | $16.0M | $8.8M | $38.0K | $154.0K |
| Operating Income | $-15.9M | $-8.8M | $-38.0K | $-154.0K |
| R&D | $10.1M | $4.8M | $0 | — |
| G&A | $5.9M | $3.5M | $38.0K | $154.0K |
| Stock-Based Comp | $15.7M | $8.1M | $0 | — |
| Other OpEx | $-2.1K | $492.0K | $0 | $0 |
| Non-Operating Income | $0 | $-3.2K | $-4.3K | $52.9K |
| Interest Expense | $358 | $3.2K | — | — |
| Pre-Tax Income | $-15.9M | $-8.8M | $-42.3K | $-101.1K |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-15.9M | $-8.8M | $-42.3K | $-101.1K |
| Discontinued Ops | $0 | $17.6M | $0 | $0 |
| Net Income | $-15.9M | $8.8M | $-42.3K | $-101.1K |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-15.9M | $8.8M | $-42.3K | $-101.1K |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $657.5K | $1.6K | $5.1K | $14.1K |
| Accounts Receivable | — | $0 | — | — |
| Other Current Assets | — | $1.6K | — | — |
| Long-Term Assets | $29.9K | $56.8K | $26.9K | $0 |
| Operating Leases | $25.7K | $52.2K | $26.9K | $0 |
| Other LT Assets | $4.2K | $4.6K | $0 | $0 |
| Total Assets | $687.5K | $58.5K | $32.0K | $14.1K |
| Current Liabilities | $201.1K | $288.6K | $326.9K | $401.1K |
| Current Leases | $25.7K | $25.3K | $26.9K | $0 |
| Other Current Liab | $175.4K | $263.2K | $300.0K | $401.1K |
| Long-Term Liabilities | $0 | $26.9K | $0 | $0 |
| LT Operating Leases | $0 | $26.9K | $0 | — |
| Other LT Liab | $0 | $0 | $0 | — |
| Total Liabilities | $201.1K | $315.5K | $326.9K | $401.1K |
| Shareholders' Equity | $486.4K | $-257.0K | $-295.0K | $-387.0K |
| Paid-In Capital | $32.3M | $32.3M | $32.3M | $32.3M |
| Retained Earnings | $-23.8M | $-32.6M | $-32.7M | $-32.8M |
| Total L&E | $687.5K | $58.5K | $32.0K | $14.1K |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-15.9M | $8.8M | $-42.3K | $-101.1K |
| Non-Cash Adjustments | $15.7M | $-8.7M | $6.8K | $-72.9K |
| Working Capital Changes | $12.9K | $-80.2K | $-1.2K | $-22.3K |
| Cash from Operations | $-147.5K | $-15.4K | $-36.7K | $-196.3K |
| Cash from Investing | $0 | $0 | $0 | $0 |
| Cash from Financing | $58.1K | $10.0K | $36.8K | $199.9K |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-89.4K | $-5.5K | $100 | $3.6K |
| Beginning Cash | $95.2K | $5.9K | $376 | $476 |
| Ending Cash | $5.9K | $376 | $476 | $4.1K |
Frequently Asked Questions
How does ACRO BIOMEDICAL CO., LTD. make money?
1) Proprietary Medical Device Development focused on innovative hardware for clinical settings, 2) Diagnostic Solutions providing specialized testing platforms, and 3) Strategic Licensing Partnerships aimed at monetizing intellectual property rights without direct sales volume.
What are the main risks for ACBM?
1) Severe liquidity crisis with negative working capital and a massive liability-to-asset ratio exceeding 2800%, 2) Total revenue collapse to zero in the latest reported period indicating business model disruption, 3) Accumulated deficit of over $32.8M threatening solvency without immediate external financing, 4) Lack of recent operating cash flow leading to potential insolvency if capital raises fail.
What is ACBM's competitive advantage?
1) Proprietary technology platform offering unique solutions not easily replicated by larger competitors, 2) Low overhead structure allowing flexibility in resource allocation despite current cash flow issues, and 3) Potential for high-margin upside if new products achieve regulatory approval and commercial traction.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.